ProPhase Labs

ProPhase Labs

ProPhase Labs was founded in 1989 originally as Quigley Corporation, making its name with the Cold-EEZE zinc gluconate lozenge brand. Ted Karkus, who assumed leadership in 2012, reoriented the publicly traded company toward a more diversified healthcare model. The firm operates from Garden City, New York, with a subsidiary lab in Nebraska. ProPhase deploys capital across three primary segments: consumer health products, genomics and molecular diagnostics, and biotechnology venture investments. The consumer division still markets Cold-EEZE, but the diagnostics arm, ProPhase Diagnostics, became the company's largest revenue driver during the pandemic through high-volume PCR testing and antibody screening. The firm's strategy also extends to early-stage therapeutics; its subsidiary ProPhase BioPharma holds equity stakes in biotech ventures. Confirmed positions include a $500,000 investment in stem-cell therapy developer LCRT Biosciences (per court filings, 2023). Geographically, operations are concentrated in the United States, with lab services deployed nationally through corporate and government testing contracts. The diagnostics segment employs its own CLIA-certified laboratory facility in Omaha, Nebraska, which at its peak processed thousands of tests daily. The company also operates a manufacturing arm, Pharmaloz, which produces contract lozenge and dietary supplement products for third parties. In February 2023, ProPhase announced a restructuring of its diagnostics operations to cut costs after federal Covid-19 emergency declarations expired, signaling a shift back toward supplement manufacturing and biopharma incubation. The company's structural differentiator is its hybrid model as a publicly traded incubator: unlike pure-play diagnostic firms or consumer brands, ProPhase uses its legacy manufacturing cash flows to fund opportunistic clinical lab buildouts and minority biotech positions, pivoting the balance sheet rapidly toward regulatory or public health tailwinds.